- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01965054
The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy
Intrahepatic cholestasis of pregnancy (ICP) is a unique disease of the liver resulting in abnormal bile acid levels and liver function. The incidence of ICP ranges from 0.1 - 15.6%. Women diagnosed with ICP most often present with itching, which may be severe. More concerning, however, is the impact of ICP on adverse fetal and pregnancy outcomes, including preterm delivery, meconium exposure, fetal demise, and increased neonatal respiratory complications. The risk for fetal demise has been estimated to be 1-3%. The mechanism of fetal demise in ICP is unknown, and therefore cannot be reliably predicted. There is evidence to suggest that extremely elevated bile acids levels are associated with worse fetal outcomes, particularly levels greater than 40 μmol/L.
Ursodeoxycholic acid (UDCA) has anticholestatic effects, and is used to treat a variety of cholestatic liver diseases. Many studies have demonstrated superiority of UDCA over other agents, including dexamethasone and cholestyramine, for relief of maternal pruritus, improvement in transaminitis, reduction in serum bile acid concentrations, and improved pregnancy outcomes. As a result, UDCA is now widely used as first-line treatment for symptomatic relief in patients with ICP.
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are two omega-3 long chain polyunsaturated fatty acids found in fish. DHA is known to play a key role in early fetal brain development, and has been associated with modest beneficial effects on neurodevelopmental and cognitive outcomes in children. In neonates with parental nutrition-induced cholestasis (PN-cholestasis), parental fish oil has been shown to be hepatoprotective not only for treatment of PN-cholestasis, but for prevention of cholestasis in premature infants at risk for the disease. Our hypothesis is that fish oil supplementation with DHA in women with ICP who are treated with UDCA will increase the rate of decline in serum total bile acid levels.
The incidence of ICP at a single hospital center in Queens, NY is estimated to be 5% secondary to a high concentration of patients from high-risk ethnic groups. High risk patients with bile acid levels greater than or equal to 40 μmol/L are managed aggressively with inpatient admission for continuous fetal monitoring, treatment with UDCA, and serial total bile acid levels weekly. These are patients are routinely offered early delivery after documented fetal lung maturity between 36 and 37 weeks gestation, or for any signs of fetal distress. This study is a prospective randomized controlled trial comparing weekly serum total bile acid levels in women admitted for inpatient management of ICP among women supplemented with a standard prenatal vitamin versus supplementation with a prenatal vitamin and DHA.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All pregnant women aged 18 years or older admitted to Elmhurst Hospital Center (EHC) for inpatient management of ICP due to a serum total bile acid level > 40 μmol/L, or serum total bile acid level > 10 μmol/L with elevated AST or ALT, are eligible for enrollment
Exclusion Criteria:
- Women < 18 years
- Women with allergies to fish
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fish Oil Supplement Group
Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
|
1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
Other Names:
|
No Intervention: Control Group
Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bile acid levels
Time Frame: up to 9 months
|
reduction in bile acid levels.
Weekly (as part of standard hospital laboratory protocol for admission with intrahepatic cholestasis of pregnancy)
|
up to 9 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Katherine Kohari, MD, Icahn School of Medicine at Mount Sinai
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 12-1542
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrahepatic Cholestasis of Pregnancy
-
Sisli Hamidiye Etfal Training and Research HospitalUnknown
-
Turku University HospitalCompletedPregnancy | Intrahepatic CholestasisFinland
-
University of BolognaWithdrawnIntrahepatic Cholestasis of PregnancyItaly
-
Epsom and St Helier University Hospitals NHS TrustKing's College Hospital NHS Trust; Medway NHS Foundation TrustUnknownPregnancy Complications | Intrahepatic Cholestases
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonUnknownIntrahepatic Cholestasis of Pregnancy | Cholestasis of Pregnancy | Obstetric CholestasisUnited Kingdom
-
Daping Hospital and the Research Institute of Surgery...maternal and child health hospital of Yong Chuan DistrictCompletedIntrahepatic Cholestasis of PregnancyChina
-
Zekai Tahir Burak Women's Health Research and Education...Unknown
-
University Hospital, ToursCompletedIntrahepatic Cholestasis of PregnancyFrance
-
MetaboGen ABSkane University Hospital; Stockholm South General HospitalCompletedIntrahepatic Cholestasis of PregnancySweden
-
Peking UniversityNot yet recruitingCholestasis | Intrahepatic Cholestasis of PregnancyChina
Clinical Trials on Fish Oil Supplement Group
-
University of TorontoCanadian Institutes of Health Research (CIHR); Diabetes Canada; Diabetes and...UnknownMyocardial Infarction | Cardiovascular Diseases | Heart Failure | Stroke | Arrhythmia | Type2 DiabetesCanada
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompleted
-
University of MichiganNational Center for Complementary and Integrative Health (NCCIH)Completed
-
The Adelaide and Meath HospitalUniversity College DublinCompletedPolycystic Ovary SyndromeIreland
-
University of CopenhagenAnjo A/SCompletedObesity | Cardiovascular Disease | Metabolic Syndrome | Growth | Blood Pressure
-
DSM Nutritional Products, Inc.Completed
-
National Science Council, TaiwanCompletedMajor Depressive DisorderTaiwan
-
Rigshospitalet, DenmarkDanish Child Cancer FoundationRecruitingLeukemia, Acute LymphoblasticDenmark
-
Tufts UniversityPrevention PharmaceuticalsTerminated
-
Liverpool John Moores UniversityCompleted